A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma

LESSONS LEARNED. The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group. The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients with metastatic KRAS mutant colorectal carci...

Descripción completa

Detalles Bibliográficos
Autores principales: Hecht, J. Randolph, Benson, Al B., Vyushkov, Dmitry, Yang, Yingsi, Bendell, Johanna, Verma, Udit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344646/
https://www.ncbi.nlm.nih.gov/pubmed/28246207
http://dx.doi.org/10.1634/theoncologist.2016-0479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344646/
https://www.ncbi.nlm.nih.gov/pubmed/28246207
http://dx.doi.org/10.1634/theoncologist.2016-0479

Ejemplares similares